S&P 500   3,329.67 (+0.27%)
DOW   29,228.12 (+0.11%)
QQQ   224.83 (+0.69%)
AAPL   319.52 (+0.93%)
FB   222.36 (+0.41%)
MSFT   166.47 (-0.02%)
GOOGL   1,492.25 (+0.67%)
AMZN   1,894.82 (+0.15%)
CGC   24.31 (+0.66%)
NVDA   251.98 (+1.63%)
BABA   223.65 (+0.63%)
MU   59.70 (+1.24%)
GE   11.36 (-2.57%)
TSLA   587.70 (+7.40%)
AMD   51.77 (+1.41%)
T   39.07 (+1.40%)
ACB   2.04 (+1.49%)
F   9.20 (-0.22%)
NFLX   329.47 (-2.56%)
PRI   126.57 (+0.13%)
BAC   34.32 (+0.15%)
DIS   144.00 (+0.31%)
GILD   63.12 (+0.78%)
S&P 500   3,329.67 (+0.27%)
DOW   29,228.12 (+0.11%)
QQQ   224.83 (+0.69%)
AAPL   319.52 (+0.93%)
FB   222.36 (+0.41%)
MSFT   166.47 (-0.02%)
GOOGL   1,492.25 (+0.67%)
AMZN   1,894.82 (+0.15%)
CGC   24.31 (+0.66%)
NVDA   251.98 (+1.63%)
BABA   223.65 (+0.63%)
MU   59.70 (+1.24%)
GE   11.36 (-2.57%)
TSLA   587.70 (+7.40%)
AMD   51.77 (+1.41%)
T   39.07 (+1.40%)
ACB   2.04 (+1.49%)
F   9.20 (-0.22%)
NFLX   329.47 (-2.56%)
PRI   126.57 (+0.13%)
BAC   34.32 (+0.15%)
DIS   144.00 (+0.31%)
GILD   63.12 (+0.78%)
S&P 500   3,329.67 (+0.27%)
DOW   29,228.12 (+0.11%)
QQQ   224.83 (+0.69%)
AAPL   319.52 (+0.93%)
FB   222.36 (+0.41%)
MSFT   166.47 (-0.02%)
GOOGL   1,492.25 (+0.67%)
AMZN   1,894.82 (+0.15%)
CGC   24.31 (+0.66%)
NVDA   251.98 (+1.63%)
BABA   223.65 (+0.63%)
MU   59.70 (+1.24%)
GE   11.36 (-2.57%)
TSLA   587.70 (+7.40%)
AMD   51.77 (+1.41%)
T   39.07 (+1.40%)
ACB   2.04 (+1.49%)
F   9.20 (-0.22%)
NFLX   329.47 (-2.56%)
PRI   126.57 (+0.13%)
BAC   34.32 (+0.15%)
DIS   144.00 (+0.31%)
GILD   63.12 (+0.78%)
S&P 500   3,329.67 (+0.27%)
DOW   29,228.12 (+0.11%)
QQQ   224.83 (+0.69%)
AAPL   319.52 (+0.93%)
FB   222.36 (+0.41%)
MSFT   166.47 (-0.02%)
GOOGL   1,492.25 (+0.67%)
AMZN   1,894.82 (+0.15%)
CGC   24.31 (+0.66%)
NVDA   251.98 (+1.63%)
BABA   223.65 (+0.63%)
MU   59.70 (+1.24%)
GE   11.36 (-2.57%)
TSLA   587.70 (+7.40%)
AMD   51.77 (+1.41%)
T   39.07 (+1.40%)
ACB   2.04 (+1.49%)
F   9.20 (-0.22%)
NFLX   329.47 (-2.56%)
PRI   126.57 (+0.13%)
BAC   34.32 (+0.15%)
DIS   144.00 (+0.31%)
GILD   63.12 (+0.78%)
Log in
(Ad)
A devastating technical glitch could crush the next generation of wireless technology before it even launches. With trillions of dollars and millions of jobs at stake, one company with the "5G fix" could put as much as $234,770 in your pocket this year. But Wall Street vultures are circling... you'll need to move quickly or risk missing this $5 bargain.

NASDAQ:TROV - TrovaGene Stock Price, Forecast & News

$1.72
+0.15 (+9.55 %)
(As of 01/22/2020 01:04 PM ET)
Add
Compare
Today's Range
$1.65
Now: $1.72▼
$1.80
50-Day Range
$1.19
MA: $1.31▼
$1.57
52-Week Range
$0.88
Now: $1.72▼
$9.65
Volume22,764 shs
Average Volume293,563 shs
Market Capitalization$13.31 million
P/E RatioN/A
Dividend YieldN/A
Beta0.17
Trovagene, Inc, a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor. The PCM-075 is in Phase Ib/II clinical trial in acute myeloid leukemia (AML) and has completed a Phase I clinical trial in advanced solid tumors. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TROV
Previous Symbol
CUSIPN/A
CIK1213037
Webhttp://www.trovagene.com/
Phone858-952-7570

Debt

Debt-to-Equity Ratio0.16
Current Ratio2.39
Quick Ratio2.39

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$380,000.00
Price / Sales35.03
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.63 per share
Price / Book0.65

Profitability

EPS (Most Recent Fiscal Year)($8.26)
Net Income$-16,460,000.00
Net Margins-3,797.67%
Return on Equity-185.18%
Return on Assets-119.86%

Miscellaneous

EmployeesN/A
Outstanding Shares7,740,000
Market Cap$13.31 million
Next Earnings Date3/4/2020 (Estimated)
OptionableOptionable

Receive TROV News and Ratings via Email

Sign-up to receive the latest news and ratings for TROV and its competitors with MarketBeat's FREE daily newsletter.

NASDAQ:TROV Rates by TradingView

(Ad)

Join a small community of investors looking for the next big winner. Every Sunday reveals 3 compelling stocks that should be on your radar for the week ahead. Sign up here to see what stocks have made it to our watchlist this week.

TrovaGene (NASDAQ:TROV) Frequently Asked Questions

What is TrovaGene's stock symbol?

TrovaGene trades on the NASDAQ under the ticker symbol "TROV."

When did TrovaGene's stock split? How did TrovaGene's stock split work?

TrovaGene shares reverse split on Wednesday, February 20th 2019. The 1-6 reverse split was announced on Tuesday, February 19th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 19th 2019. An investor that had 100 shares of TrovaGene stock prior to the reverse split would have 17 shares after the split.

How were TrovaGene's earnings last quarter?

TrovaGene Inc (NASDAQ:TROV) released its quarterly earnings results on Thursday, November, 7th. The medical research company reported ($0.71) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.84) by $0.13. The medical research company earned $0.05 million during the quarter. TrovaGene had a negative return on equity of 185.18% and a negative net margin of 3,797.67%. View TrovaGene's Earnings History.

When is TrovaGene's next earnings date?

TrovaGene is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for TrovaGene.

What price target have analysts set for TROV?

2 Wall Street analysts have issued 12-month price objectives for TrovaGene's stock. Their forecasts range from $6.00 to $23.00. On average, they anticipate TrovaGene's share price to reach $14.50 in the next year. This suggests a possible upside of 748.0% from the stock's current price. View Analyst Price Targets for TrovaGene.

What is the consensus analysts' recommendation for TrovaGene?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TrovaGene in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TrovaGene.

What are Wall Street analysts saying about TrovaGene stock?

Here are some recent quotes from research analysts about TrovaGene stock:
  • 1. Maxim Group analysts commented, "Trovagene reported 2Q19 with a net loss of ($4.1M) and ended the period with $10.8M in cash on the balance sheet." (8/9/2019)
  • 2. According to Zacks Investment Research, "Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA. Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. " (5/9/2019)

Has TrovaGene been receiving favorable news coverage?

Media stories about TROV stock have trended very negative this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. TrovaGene earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned media headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for TrovaGene.

Who are some of TrovaGene's key competitors?

What other stocks do shareholders of TrovaGene own?

Who are TrovaGene's key executives?

TrovaGene's management team includes the folowing people:
  • Dr. Thomas H. Adams, CEO & Exec. Chairman (Age 76)
  • Dr. Mark Erlander, Chief Scientific Officer (Age 59)
  • Ms. Elizabeth Anderson, VP of Fin. & Admin.
  • Mr. George Samuel, VP & Gen. Counsel
  • Ms. Vicki Kelemen, VP of Corp. Communications

Who are TrovaGene's major shareholders?

TrovaGene's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Wedbush Securities Inc. (0.33%). Company insiders that own TrovaGene stock include Rodney S Markin and Stanley Tennant. View Institutional Ownership Trends for TrovaGene.

Which institutional investors are buying TrovaGene stock?

TROV stock was acquired by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. Company insiders that have bought TrovaGene stock in the last two years include Rodney S Markin and Stanley Tennant. View Insider Buying and Selling for TrovaGene.

How do I buy shares of TrovaGene?

Shares of TROV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is TrovaGene's stock price today?

One share of TROV stock can currently be purchased for approximately $1.71.

How big of a company is TrovaGene?

TrovaGene has a market capitalization of $13.24 million and generates $380,000.00 in revenue each year. The medical research company earns $-16,460,000.00 in net income (profit) each year or ($8.26) on an earnings per share basis. View Additional Information About TrovaGene.

What is TrovaGene's official website?

The official website for TrovaGene is http://www.trovagene.com/.

How can I contact TrovaGene?

TrovaGene's mailing address is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. The medical research company can be reached via phone at 858-952-7570 or via email at [email protected]


MarketBeat Community Rating for TrovaGene (NASDAQ TROV)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  375 (Vote Outperform)
Underperform Votes:  273 (Vote Underperform)
Total Votes:  648
MarketBeat's community ratings are surveys of what our community members think about TrovaGene and other stocks. Vote "Outperform" if you believe TROV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TROV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2020 by MarketBeat.com Staff

Featured Article: What is a Buy-Side Analyst?
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel